GENT, Belgium & NEW YORK--(BUSINESS WIRE)--The International AIDS Vaccine Initiative (IAVI) and Algonomics today announced a collaboration to modify an HIV protein in order to improve immune responses elicited by HIV vaccine candidates that include the protein as an insert. The project utilizes a proprietary antigen design technology developed by Algonomics and will be funded by IAVI’s Innovation Fund, a funding mechanism that seeks out novel and typically high-risk technologies that could provide breakthroughs in the design and development of novel AIDS vaccine candidates.
